FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of August 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca prices
a $3bn bond issue
4 August 2020 07:00 BST
AstraZeneca prices a $3bn bond issue
AstraZeneca PLC announces that, on 3 August 2020, it priced a three
tranche global bond offering totalling $3bn. The offering is
expected to close on 6 August 2020, subject to customary closing
conditions. AstraZeneca expects to use the net proceeds of the
issue for general corporate purposes, which may include the
refinancing of existing indebtedness. The transaction, which is a
global offering registered with the US Securities and Exchange
Commission (SEC), consists of the following three
tranches:
●
$1.2bn
of fixed rate notes with a coupon of 0.700%, maturing 8 April
2026;
●
$1.3bn
of fixed rate notes with a coupon of 1.375%, maturing 6 August
2030; and
●
$0.5bn
of fixed rate notes with a coupon of 2.125%, maturing 6 August
2050.
BofA Securities, Inc., HSBC Securities (USA) Inc. and Mizuho
Securities USA LLC acted as joint book-running managers on the
transaction and Barclays Capital Inc., Citigroup Global Markets
Inc., Deutsche Bank Securities Inc., Goldman Sachs & Co. LLC,
J.P. Morgan Securities LLC and Morgan Stanley and Co. LLC acted as
co-managers on the transaction. The notes will be issued under
AstraZeneca's effective shelf registration statement on Form F-3,
which AstraZeneca filed with the SEC on 8 November 2019. The
offering is being made solely by means of the prospectus contained
within that shelf-registration statement, along with a prospectus
supplement forming part of the effective registration statement,
which investors should read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting BofA
Securities, Inc. at 1-800-294-1322, HSBC Securities (USA) Inc. at
1-866-811-8049, or Mizuho Securities USA LLC at 1-866-271-7403.
Readers may also download these documents for free by visiting the
Electronic Data Gathering, Analysis, and Retrieval (EDGAR) system
on the SEC website at www.sec.gov.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact the Company's financial guidance
for 2020.
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. For more information, please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Cautionary Statements Regarding Forward-Looking
Statements
This announcement contains certain forward-looking statements with
respect to the operations, performance and financial condition of
AstraZeneca. Although the Company believes its expectations are
based on reasonable assumptions, any forward-looking statements, by
their very nature, involve risks and uncertainties and may be
influenced by factors that could cause actual outcomes and results
to be materially different from those predicted. The
forward-looking statements reflect knowledge and information
available at the date of preparation of this announcement and
AstraZeneca undertakes no obligation to update these
forward-looking statements.
Contacts
For details on how to contact the Investor Relations Team,
please click
here. For Media
contacts, click
here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
4 August
2020
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|